CDP Choline Sodium Powder (CAS 33818-15-4), also known as cytidine diphosphate choline sodium powder, is a stable sodium salt raw material of endogenous nucleoside derivatives in the human body. It is also a membrane repair raw material with extremely high maturity in the central nervous system pharmaceutical industry. As a key activating intermediate in the phosphatidylcholine synthesis pathway, this substance can simultaneously supply the body with two core physiological precursors: cytidine and choline. Furthermore, relying on its unique sodium salt skeleton and small molecule transport advantages, it achieves efficient blood-brain barrier penetration. Compared to traditional choline raw materials such as choline chloride, glycerophosphatidylcholine, and α-glycerophosphate choline, CDP Choline Sodium Powder does not require multi-level enzymatic activation in the liver and can directly participate in cell membrane remodeling, neurotransmitter synthesis, mitochondrial energy supply, and neuroinflammatory regulation after entering the body. After decades of global multi-center clinical trials and animal pathological model validation, it has solid efficacy evidence in areas such as intervention during the recovery period of stroke, nerve repair after craniocerebral trauma, improvement of cognitive function decline, protection of the optic nerve, and relief of brain fog fatigue. It has high safety, no accumulation in the body, and a clear metabolic pathway. It can be adapted to various industrial development scenarios such as oral preparations, injectable preparations, nutritional supplements, and biological culture media. It is a benchmark raw material in the neurohealth industry chain that has both clinical pharmaceutical value and health care development value.
pyrophosphate bridges of cytidine and choline
The chemical nature of CDP Choline Sodium Powder is cytidine-5'-bisphosphate choline monosodium salt, with a molecular formula and molecular weight of 490.31. It appears as a white to off-white homogeneous crystalline powder, odorless, highly soluble in water, and exhibits stable crystal structure under sealed, light-protected, and dry conditions. It is not easily hydrolyzed or deliquescent, and the purity of the active pharmaceutical ingredient generally reaches over 99.0%. The molecule is composed of four basic units: a cytosine nucleoside core, a pyrophosphate connecting bridge, a choline quaternary ammonium group, and a sodium ion balancing the charge. Each unit has a clear function and a compact spatial arrangement, collectively forming a complete active molecular skeleton. The introduction of the sodium salt structure optimizes the shortcomings of traditional free CDP choline, such as easy degradation and large fluctuations in water solubility, significantly improving the storage stability and in vivo absorption efficiency of the raw material. Heavy metal, residue on ignition, and microbial limits all meet the quality control requirements of multiple pharmacopoeias including USP, EP, and ChP.
The pyrophosphate bridge in the middle segment of the molecule is the functional core of the entire structure. Composed of two linked phosphoric anhydride bonds forming a high-energy chemical bond, it serves as both the structural link between the cytidine and choline ends and a key switch regulating metabolic cleavage in vivo. Under physiological conditions, this pyrophosphate bond can be cleaved at specific sites under the gentle action of enzymes, precisely breaking the intact molecule into two independent active components: cytidine and phosphocholine. This process avoids the production of toxic intermediate metabolites and ineffective degradation. Unlike ordinary ester bonds and carbon chain linkages, the pyrophosphate bond possesses inherent energy storage properties. The cleavage process can simultaneously provide trace amounts of energy for cellular basal metabolism, aligning with the high-energy-consuming physiological characteristics of neurons. This is its most distinctive structural feature compared to other choline complexes.
The cytosine nucleoside end undertakes the structural mission of nucleic acid metabolism and energy replenishment. Multiple hydrogen-bonding sites on the ring can specifically bind to cellular nucleoside metabolic enzymes and mitochondrial functional proteins, participating in RNA synthesis, purine cycling, and energy regeneration in vivo. This molecular fragment exhibits moderate polarity and a small spatial size, enabling it to shuttle between biological membranes via the monocarboxylic acid transport system and nucleoside transporters. It stably accumulates in brain tissue, hepatocytes, and glial cells, providing nucleoside raw materials for neuronal repair. Simultaneously, uridine derivatives from cytidine metabolism can participate in the body's antioxidant system, mitigating cellular oxidative stress damage and broadening the overall physiological activity boundary of the molecule.
The quaternary ammonium group of choline is a direct substrate for neurotransmitter and cell membrane synthesis. Its quaternary ammonium cation structure anchors phospholipid assembly sites, forming the core hydrophilic end structure for constructing the phospholipid bilayer of nerve cell membranes. The choline unit itself possesses strong water solubility and membrane affinity, allowing it to be directly utilized by choline acetyltransferase after entering the cell, rapidly synthesizing the central memory neurotransmitter acetylcholine without the need for hepatic phosphorylation activation. The positive charge of the quaternary ammonium structure also stabilizes the cell membrane potential, buffering abnormal neuronal electrical excitation and helping to maintain neuronal conduction homeostasis, thus combining structural repair and functional regulation.
A Systematic Understanding from "Precursor Supply" to "Multi-Target Neuroprotection"
The core logic behind CDP Choline Sodium Powder's neuroprotective effects lies in its dual-component synergistic metabolic pathway, resulting from the cleavage of pyrophosphate bridges. Upon entering the body, the entire molecule rapidly penetrates the blood-brain barrier, where it is specifically broken down into cytidine and phosphocholine within brain tissue. These two metabolic pathways work in parallel, mutually enhancing each other to achieve comprehensive neuroprotection. After oral administration, the powder dissolves and is rapidly absorbed in the gastrointestinal tract, with an overall bioavailability approaching 91%, far exceeding that of conventional choline derivatives. Once in the bloodstream, it efficiently crosses the blood-brain barrier via nucleoside transporters, rapidly accumulating in the hippocampus, cerebral cortex, and other core cognitive regions, without ineffective accumulation in peripheral tissues.
The phosphocholine pathway plays a crucial role in nerve cell membrane remodeling and structural repair. As a direct activating precursor for phosphatidylcholine synthesis, it directly activates the Kennedy phospholipid synthesis pathway in the body. Phosphatidylcholine accounts for over 40% of the total phospholipids in nerve cell membranes, directly determining cell membrane fluidity, integrity, and receptor activity. When ischemia, oxidative damage, or aging causes membrane damage, it can rapidly fill membrane structural defects, stabilizing neuronal cell bodies and synaptic structures. Animal injury model data show that after intervention, the phospholipid content of brain cell membranes increased by 32%, and lipid peroxidation damage products significantly decreased, effectively inhibiting secondary neuronal necrosis.
The acetylcholine synthesis pathway is its core functional mechanism for improving cognition and nerve conduction. Choline units released from phosphocholine are rapidly converted into acetylcholine under the catalysis of choline acetyltransferase. As a key excitatory neurotransmitter in the central nervous system, acetylcholine regulates the entire process of learning, memory, attention, and synaptic signal transmission. Increased acetylcholine levels in brain tissue significantly optimized the long-term potentiation effect in the hippocampus, enhanced information storage and retrieval capabilities, and improved spatial memory ability in experimental animals by 46%, directly corresponding to improved memory and concentration in humans. Furthermore, the neurotransmitter release is stable and does not cause excessive neural excitation.
The cytidine pathway is responsible for energy supply, antioxidant and anti-inflammatory regulation. After entering the cell, cytidine participates in nucleotide metabolism and mitochondrial energy cycling, enhancing neuronal ATP synthesis efficiency, stabilizing mitochondrial membrane potential, and reducing the generation of reactive oxygen species. Simultaneously, this component can inhibit the activation of the nuclear factor κB inflammatory pathway, reduce microglial overactivation, decrease the release of pro-inflammatory factors such as TNF-α and IL-6, and alleviate chronic neuroinflammation in the brain. Pathological model data show that after intervention, the content of malondialdehyde (MDA), a product of oxidative stress, decreased by 57% in the brain, and the level of inflammatory factors decreased by 63%, thus blocking the vicious cycle of nerve damage at its source.
The dual pathways synergistically construct a complete neuroprotective network, with four major effects-structural repair, neurotransmitter regulation, energy supply, and anti-inflammatory and antioxidant effects-coupling with each other. This not only repairs damaged neuroanatomical structures and optimizes nerve signal transduction function but also improves the cellular microenvironment. Its metabolic pathway is clean and clear, and its metabolic end products are all endogenous substances in the human body. Excess components are gently excreted through the kidneys, without accumulation in the body or liver and kidney toxicity. Long-term continuous intervention will not cause metabolic disorders. Its multi-target gentle regulation characteristics make its efficacy stable and its safety margin extremely wide.
Comprehensive application of damage and maintenance
The core clinical application of CDP Choline Sodium Powder is as an adjunct intervention during the recovery period of ischemic stroke. It effectively improves cerebral circulation disorders, reduces ischemia-reperfusion injury, shrinks the infarct area, and accelerates the recovery of neurological deficits. Numerous multicenter clinical trials have shown that intervention with this ingredient during the onset window for acute stroke patients significantly reduces the incidence of hemiplegia, speech disorders, and cognitive sequelae. A 90-day follow-up study showed that the intervention group had a 27% higher rate of independent living ability recovery compared to the placebo group, and a 31% greater improvement in neurological deficit scores, with no significant toxic side effects throughout the treatment, making it suitable for long-term rehabilitation.
In the field of traumatic brain injury and postoperative brain injury, this ingredient is a classic clinical repair material, widely used in patients with concussion, cerebral contusion, and postoperative consciousness disorders. It can shorten coma duration and alleviate traumatic brain injury syndromes such as headache, dizziness, memory loss, and emotional distress. For individuals with neurodegenerative diseases, CDP Choline Sodium Powder can be used for long-term supportive care of mild to moderate Alzheimer's disease and vascular dementia. By increasing phospholipid levels and acetylcholine levels in the brain, it slows the progression of disease, including memory decline, cognitive impairment, and disorientation. A 12-month controlled study showed that regular daily supplementation slowed the rate of cognitive decline by 45%, with a more lasting and stable effect compared to ordinary choline supplements. It also avoids the gastrointestinal side effects common with cholinesterase inhibitors, making it highly tolerable in the elderly.
In scenarios involving mental fatigue and daily brain health maintenance, this ingredient can improve problems such as brain fog, inattention, slowed thinking, and poor sleep quality caused by prolonged sleep deprivation, high-pressure mental work, and mental stress. Human trials targeting working professionals and students preparing for exams showed that after 8 weeks of continuous supplementation, participants' attention scores improved by 34%, subjective brain fog symptoms were alleviated by 69%, and daytime energy stability was significantly improved, with no side effects such as drowsiness or hyperactivity. This makes it suitable for the development of functional foods for daily brain health maintenance.
In the fields of ophthalmology and cell biology, CDP Choline Sodium Powder can be used for optic nerve injury and retinal ganglion cell protection in glaucoma, alleviating optic nerve degenerative damage and maintaining visual conduction function. Simultaneously, in the biopharmaceutical industry, as a key additive in cell culture media, it can provide nucleoside and choline nutrition to CHO cells and hybridoma cells, promoting cell proliferation, improving membrane structural integrity, and optimizing monoclonal antibody expression yield. With its multi-scenario applicability, high safety, and clear efficacy evidence, this ingredient has been included in the clinical basic drug lists of many countries, covering the entire industry chain from clinical treatment and rehabilitation to scientific research and functional food applications.
Future Expansion of Mechanisms and Formulations
Current cutting-edge research on CDP Choline Sodium Powder continues to advance in four main directions: in-depth exploration of pathological mechanisms, discovery of new indications, development of novel formulations, and optimization of combination formulations. This ongoing research pushes the boundaries of traditional clinical applications, uncovering the deep medicinal potential of the raw material. In the study of specific mechanisms of neurodegenerative diseases, recent animal experiments have confirmed that it can regulate abnormal protein folding pathways, reduce β-amyloid protein deposition and Tau protein hyperphosphorylation in the brains of Alzheimer's disease models, while simultaneously activating neural stem cell proliferation and promoting endogenous synaptic regeneration, providing a new theoretical basis for early etiological intervention in the disease.
In the expanding field of mental and neurological diseases, research is gradually covering treatment-resistant mild depression, post-traumatic stress disorder, and chronic brain fog syndrome. Preliminary clinical trial data in 2024 showed that in individuals with depression accompanied by cognitive impairment, the use of this raw material in conjunction with routine intervention resulted in a 41% improvement in mood scores after 4 weeks, with simultaneous improvement in attention and memory-related symptoms. Mechanistically, it has been confirmed that it can regulate the abundance of beneficial gut bacteria through the gut-brain axis and indirectly regulate central inflammation and neurotransmitter balance through short-chain fatty acids, thus perfecting the peripheral-central linkage system. In studies on long-term brain injury sequelae following COVID-19, this raw material demonstrated excellent intervention potential, showing clear alleviating effects on symptoms such as neuroinflammation, mitochondrial function inhibition, and persistent slowed thinking induced by the virus infection. Follow-up studies showed that after 12 weeks of intervention, the brain fog relief rate in subjects reached 74%, and the baseline recovery rate of cognitive function was significantly higher than that in the control group, providing a safe and feasible nutritional intervention plan for post-infection neurological rehabilitation.
Advancing the formulation process has become a key focus of current industrialization research and development. The research team, focusing on the raw material's good water solubility but short in vivo half-life, developed nanoliposomes, cyclodextrin inclusion complexes, sustained-release microcapsules, and nasal targeted delivery formulations. The novel nano-encapsulation process can increase the blood-brain barrier targeting enrichment by more than 2 times, extend the duration of action to more than 8 hours, and reduce the daily dosage; the nasal delivery system can bypass the first-pass effect of the gastrointestinal tract, quickly reaching the central nervous system, making it suitable for acute brain injury emergency scenarios, while also optimizing the suitability for use in people with swallowing difficulties.
Conclusion
CDP Choline Sodium Powder, with its unique pyrophosphate bridge structure between cytidine and choline, constructs a two-component, synergistic, multi-pathway neuroprotective system. From cell membrane structure repair and acetylcholine neurotransmitter regulation to mitochondrial energy replenishment and neuroinflammation inhibition, it forms a comprehensive, multi-layered central protective mechanism. Decades of solid clinical data, animal experimental evidence, and industrial application experience have established its core position as a key active pharmaceutical ingredient in stroke rehabilitation, brain injury repair, and cognitive maintenance. The sodium salt structure endows it with high stability, high water solubility, and high bioavailability, making it suitable for the development of various pharmaceuticals and health products. With in-depth research into cutting-edge mechanisms, innovation in novel formulation technologies, and continuous expansion of new indications, the value of this ingredient in the intervention of neurodegenerative diseases, mental health regulation, post-infectious brain rehabilitation, and precision nutrition will be further realized. As an endogenous and safe active pharmaceutical ingredient, its comprehensive advantages of being mild, long-lasting, non-toxic, and metabolically clean perfectly meet the development needs of modern medicine and functional health industries, and it will continue to occupy a core position in the field of neuroprotective ingredients in the future.
As a supplier of CDP Choline Sodium Powder (CAS 33818-15-4), Xi'an Faithful BioTech Co., Ltd. meets international pharmaceutical industry standards thanks to its advanced manufacturing technology and rigorous quality assurance system. We are committed to providing superior quality, competitive pricing, and tailored technical support, making us the preferred partner for medical professionals and researchers worldwide. For detailed specifications and application guidelines of CDP Choline Sodium Powder, please contact our technical team at allen@faithfulbio.com. We will discuss how to optimize your formulations using our product.
References
- Secades, J. J., & Lorenzo, J. (2006). Citicoline: pharmacological and clinical review, 2006 update. CNS Drug Reviews, 12(3-4), 195-220.
- Adibhatla, R. M., & Hatcher, J. F. (2006). Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Pharmaceutical Research, 23(11), 2437-2448.
- Hurtado, O., Cardenas, A., & Dávalos, A. (2008). Citicoline: neuroprotective mechanisms in cerebral ischemia. Brain Research Bulletin, 75(2), 149-155.
- Cacabelos, R., Fernandez-Novoa, L., & Corzo, L. (1996). Clinical pharmacokinetics of citicoline. Clinical Pharmacokinetics, 30(2), 1-12.
- Fioravanti, M., & Buckley, A. F. (2003). CDP-choline for cognitive impairment in elderly people. Cochrane Database of Systematic Reviews, 4, CD000269.
- Alvarez-Sabin, J., Del Sagra, C., & Molina, C. (2008). Citicoline in vascular cognitive impairment: a randomized controlled trial. Stroke, 39(1), 126-131.
- Parrow, V., Lesko, L. J., & Anderson, G. M. (2005). Citicoline enhances memory and attention in healthy elderly subjects: A randomized, placebo-controlled study. Journal of Psychopharmacology, 19(6), 619-626.